Leadership notes reiterate a human-centered, AI-enabled path to accelerate medicines through iPSC models.

By combining iPSC-based systems with advanced computing, the initiative seeks to identify patient-specific response patterns and better predict adverse drug effects, reducing time and costs in development.

Learnings and opportunities will be informed by ongoing research and publications, including Wu et al. in Science and Liu et al. in Cell, with a Computex 2026 keynote replay referenced.

Greenstone Biosciences, based in Silicon Valley and co-founded by Joseph C. Wu, focuses on NAMs, clinical genomics, iPSC platforms, organoid-based disease modeling, and AI/ML for drug development, with backing from Walden Catalyst, Mayfield, and Prosperity 7 Ventures.

Lead quotes from Joseph C. Wu emphasize identifying patient-specific response patterns and improving prediction of adverse drug effects to lower costs and shorten development timelines.

NAMs, computer models, and advanced cell-based assays are central to the approach, highlighting translational relevance in preclinical testing.

Greenstone has the world’s largest biobank of iPSCs, enabling human-centric models for drug discovery, safety assessment, and scalable data processing with Intel.

Press inquiries should contact Jade T. Chao, JD, MPH at Greenstone.

The partnership between Greenstone Biosciences and Intel aims to speed up the development of new medicines, improve drug safety, and advance precision medicine by integrating Greenstone’s human biology with Intel’s specialized silicon and computing capabilities for scalable data processing, storage, and analysis.

The collaboration will leverage human cellular models, population-scale datasets, and AI-enabled analytics to enhance drug safety assessment and accelerate discovery.

The collaboration aligns with FDA Modernization Act 3.0 momentum toward New Approach Methodologies, promoting alternatives to traditional animal testing.

Public materials include a Computex 2026 keynote, related publications (Science, Cell, Nature), and a company overview detailing NAMs, clinical genomics, iPSC platforms, and AI/ML capabilities.